PCSK9 inhibition-mediated reduction in triglyceride with evolocumab is related to baseline triglyceride levels: an analysis from 1791 patients
EA Stein, R Somaratne, C Djedjos, T Liu… - Journal of the American …, 2016 - jacc.org
Background Two decades ago all statins demonstrated effective triglyceride (TG) reductions
although mainly in hypertriglyceridemic (HTG) patients. The studies supported increased …
although mainly in hypertriglyceridemic (HTG) patients. The studies supported increased …
PCSK9 inhibition with alirocumab decreases plasma lipoprotein (a) concentration by a dual mechanism of action in statin‐treated patients with very high …
Background Inhibition of proprotein convertase subtilisin/kexin type 9 with alirocumab
decreases plasma lipoprotein (a)[Lp (a)] levels. The kinetic mechanism for lowering Lp (a) …
decreases plasma lipoprotein (a)[Lp (a)] levels. The kinetic mechanism for lowering Lp (a) …
Effect of evolocumab on lipoprotein (a) and PCSK9 in healthy individuals with elevated lipoprotein (a) level
O Afanasieva, MV Ezhov, E Klesareva… - Journal of …, 2020 - mdpi.com
Background and aims: The aim of this study was to investigate the influence of a single
injection of Evolocumab on the dynamics of Lp (a), fractions of apoB100-containing …
injection of Evolocumab on the dynamics of Lp (a), fractions of apoB100-containing …
Proprotein convertase subtilisin kexin type 9 inhibition for autosomal recessive hypercholesterolemia—brief report
A Thedrez, B Sjouke, M Passard… - … , and vascular biology, 2016 - Am Heart Assoc
Objective—Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors lower low-
density lipoprotein (LDL) cholesterol in the vast majority of patients with autosomal dominant …
density lipoprotein (LDL) cholesterol in the vast majority of patients with autosomal dominant …
The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors
V Blanchard, K Chemello, T Hollstein… - Cardiovascular …, 2022 - academic.oup.com
Abstract Aims Lipoprotein (a)[Lp (a)] is a lipoprotein species causatively associated with
atherosclerosis. Unlike statins, PCSK9 inhibitors (PCSK9i) reduce Lp (a), but this reduction …
atherosclerosis. Unlike statins, PCSK9 inhibitors (PCSK9i) reduce Lp (a), but this reduction …
Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology
MM Page, GF Watts - Expert Opinion on Drug Metabolism & …, 2015 - Taylor & Francis
Introduction: Statins are the mainstay of lipid-lowering therapies targeted at reducing
cardiovascular risk. However, they do not completely obviate risk, not all patients tolerate …
cardiovascular risk. However, they do not completely obviate risk, not all patients tolerate …
[HTML][HTML] Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses
JG Robinson, M Farnier, JJP Kastelein, EM Roth… - Journal of clinical …, 2019 - Elsevier
Background Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin
type 9 (PCSK9). Objective Changes in PCSK9, alirocumab, and low-density lipoprotein …
type 9 (PCSK9). Objective Changes in PCSK9, alirocumab, and low-density lipoprotein …
Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study
T Hollstein, A Vogt, T Grenkowitz, T Stojakovic… - Vascular …, 2019 - Elsevier
Background Proprotein convertase subtilisin-kexin type 9 inhibitors (PCSK9-I) reduce low-
density lipoprotein (LDL) cholesterol in human studies. Previous studies suggest that …
density lipoprotein (LDL) cholesterol in human studies. Previous studies suggest that …
Relationship between low‐density lipoprotein cholesterol, free proprotein convertase subtilisin/kexin type 9, and alirocumab levels after different lipid‐lowering …
J Rey, F Poitiers, T Paehler, A Brunet… - Journal of the …, 2016 - Am Heart Assoc
Background Alirocumab undergoes target‐mediated clearance via binding of proprotein
convertase subtilisin/kexin type 9 (PCSK 9). Statins increase PCSK 9 levels; the effects of …
convertase subtilisin/kexin type 9 (PCSK 9). Statins increase PCSK 9 levels; the effects of …
[HTML][HTML] Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized …
EM Roth, MR Taskinen, HN Ginsberg… - International journal of …, 2014 - Elsevier
Background Efficacy and safety of alirocumab were compared with ezetimibe in
hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other …
hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other …